ALS association wants more commitment from the FDA

ALS Association

24 June 2021 - In a response letter to the ALS Association, the U.S. FDA has recognised the unmet therapeutic need of people with amyotrophic lateral sclerosis and reaffirmed its commitment to the 2019 ALS clinical trial guidance.

However, the agency did not provide any details about how it has implemented that guidance to date — a specific request made by the association shortly after hosting a virtual meeting with the FDA in May.

Read ALS Association article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Regulation , Patient